Although trials were initially undertaken in NSCLC, the extensive use of ICI in other tumor types enabled the dissemination of PD-(L)1 PET tracer studies into SCC of the head and neck [291], renal cell carcinoma [292], Hodgkin lymphoma [293], breast cancer [294], CM [295], and other cancers. This evidence concerns the gene CD274 and neoplasm.